Data for adalimumab in ulcerative colitis after prior use of infliximab are scarce.status: publishe
To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-seve...
Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective da...
International audienceBackgroundData on the value of therapeutic drug monitoring of infliximab (IFX)...
Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose ...
Background & AimsWe analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and A...
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...
Golimumab has been approved recently to treat refractory moderate-to-severe ulcerative colitis [UC]....
Mucosal healing is an independent predictor of sustained clinical remission in patients with ulcerat...
Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...
Data on immunogenicity to adalimumab (ADL) therapy in patients with IBD is limited. We performed add...
The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory b...
Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colit...
Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treat...
Objective: Randomized controlled trials have shown the effectiveness of Adalimumab in ulcerative col...
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...
To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-seve...
Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective da...
International audienceBackgroundData on the value of therapeutic drug monitoring of infliximab (IFX)...
Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose ...
Background & AimsWe analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and A...
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...
Golimumab has been approved recently to treat refractory moderate-to-severe ulcerative colitis [UC]....
Mucosal healing is an independent predictor of sustained clinical remission in patients with ulcerat...
Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...
Data on immunogenicity to adalimumab (ADL) therapy in patients with IBD is limited. We performed add...
The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory b...
Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colit...
Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treat...
Objective: Randomized controlled trials have shown the effectiveness of Adalimumab in ulcerative col...
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...
To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-seve...
Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective da...
International audienceBackgroundData on the value of therapeutic drug monitoring of infliximab (IFX)...
DOI
Add to ORKG